Developing first-in-class
oncology drugs
leading global trend

Delivering new treatment options for patients with hard-to-treat cancers.

Competing with global
players based on
differentiated clinical PoC

Obtaining clinical evidence of extended survival and improved quality of life in cancer patients

Identifying novel targets
and developing therapeutics for
refractory cancers

Advancing as a global oncology company through the developing therapies for refractory cancers